Surg Clin North Am. 2024 Jun;104(3):673-684. doi: 10.1016/j.suc.2023.12.006.Epub 2023 Dec 26.

Maura Walsh ¹, Shahrose Rahman ², Rebecca Gologorsky ³, Vassiliki Liana Tsikitis ²

Author information

¹Department of General Surgery, Oregon Health Sciences University, 3181 Southwest Sam Jackson Park Road L-579, Portland, OR 97239, USA. Electronic address: walshma@ohsu.edu.

²Department of Surgery, Oregon Health Sciences University, 3181 Southwest Sam Jackson Park Road L-579, Portland, OR 97239, USA.

³Oregon Health Sciences University, 3181 Southwest Sam Jackson Park Road L-579, Portland, OR 97239, USA.

Abstract

Inflammatory bowel disease (IBD) is associated with an increased risk of colorectal cancer (colorectal adenocarcinoma [CRC]) compared with the general population. IBD-related CRC is related to poorer outcomes than non-IBD-related CRC, and it accounts for 10% to 15% of death in patients with IBD. As such, screening guidelines have been made specific to this population recommending shorter intervals of endoscopic screening to detect dysplasia and CRC relative to the general population. Advances in endoscopic technology allow for improved visualization of dysplasia, which has led to widespread adoption of dye-spray chromoendoscopy with targeted biopsy.